Reality Check on Growth Hormone Deficiency
Market access for growth hormone deficiency (GHD) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 55% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: When the FDA approved Novo Nordisk, Inc.’s Sogroya (somapacitanbeco) for the replacement of growth hormone in adults with growth hormone deficiency in August 2020, it became the only long-acting agent on the market. A survey by Zitter Insights shows that many endocrinologists expect to shift prescribing to such agents from the short-acting growth hormones
- Key Findings: Pediatric GHD represents the largest market for recombinant growth hormones. Contracting is prevalent among GHD products, where formulary preference drives choice
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.